Brought to you by 
AstraZeneca buys ZS Pharma for $2.7bn
09 Sep 2020
Executive Summary
AstraZeneca PLC is strengthening its cardiovascular and metabolic disease offerings through the acquisition of ZS Pharma Inc., a publicly traded US firm developing a therapy for hyperkalemia (high potassium levels). AZ is paying $90 per share (a 39% premium), or $2.7bn.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Contract
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
AstraZeneca buys ZS Pharma for $2.7bn
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice